The US Food and Drug Administration green lights a therapy for an extreme form of multidrug resistant TB.

Our resident bacteria can affect the activity of immunotherapies and other medicines in the body.

There are currently more than two dozen ongoing Phase 1 and Phase 2 trials using different vaccine platforms such as DNA, RNA, synthetic long peptides, and dendritic cells.

Through their effects on metabolism and immunity, bacteria in the gut affect whether medications will be effective for a given patient.

Five independent groups got different results in a drug-response experiment, despite sharing protocols, reagents, and cell lines. The researchers identify technical variables that could be to blame.

New ways to search for druggable RNAs and matching small molecules

Executives at a biotech that develops new antibodies argue that Ram Sasisekharan didn’t come up with the structures for at least two experimental therapies that his group has described.

Two clinical trials that altered vasopressin signaling report improved social functions in people with autism spectrum disorder, but researchers caution against overinterpreting the results.

The pharmaceutical industry is looking to machine learning to overcome complex challenges in drug development.